EP News Bureau

The company has received an approval from US FDA

The Union Budget 2018 evokes mixed reviews from the pharmaceuticals industry

The ‘Centre to Combat Antimicrobial Resistance’ in New Delhi will be set up

Clinical One Platform unifies clinical development ops, info to increase speed to market at lower cost

The net profit was at Rs 131 crores against Rs 86 crores last year

It gets product patents from Aripo & South Korea

EBITDA was at Rs. 45 crore which grew 6 times Q-o-Q and 2.5 times Y-o-Y

Q3 income from operations at Rs. 587 crore, PAT at Rs. 147 crore

PAT up by 15.38 per cent for 9 months ended in December’ 2017

Top Indian lawyers to argue Ranbaxy-Daiichi appeal in S'pore By Gurdip Singh Singapore